Monoclonal Antibodies in Immunodiagnosis and Immunotherapy最新文献

Stunning Progress in De Novo Computationally Designed Antibodies. 计算设计抗体的惊人进展。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-10-01 DOI: 10.1177/21679436251385401

Andrei Moroz, Cory L Brooks

引用次数: 0

Internal Validation of the Anti-Human Hemoglobin Antibody for Enhanced Human Blood Detection at the PFSA DNA and Serology Laboratory, Pakistan. 巴基斯坦PFSA DNA和血清学实验室用于增强人类血液检测的抗人血红蛋白抗体的内部验证。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-07-02 DOI: 10.1089/mab.2025.0002

Asad Saeed, Khurram Wajih Mehmood, Muhammad Irfan Ashiq, Sajjad Ahmad, Muhammad Sohail Anjum, Qaiser Hussain, Muhammad Amjad, Nauman Rauf

{"title":"Internal Validation of the Anti-Human Hemoglobin Antibody for Enhanced Human Blood Detection at the PFSA DNA and Serology Laboratory, Pakistan.","authors":"Asad Saeed, Khurram Wajih Mehmood, Muhammad Irfan Ashiq, Sajjad Ahmad, Muhammad Sohail Anjum, Qaiser Hussain, Muhammad Amjad, Nauman Rauf","doi":"10.1089/mab.2025.0002","DOIUrl":"10.1089/mab.2025.0002","url":null,"abstract":"Biological fluids collected from crime scenes play a crucial role in solving serious crimes such as murder, rape, burglary, and theft. Identifying human blood using various methods is crucial for linking disparate pieces of evidence and solving crimes. In this study, the Anti-Human Hemoglobin antibody (Ah-HB) from Sigma-Aldrich® USA was internally validated for human blood identification using the Ouchterlony Double Immunodiffusion (ODD) technique at the DNA and Serology Department of the Punjab Forensic Science Agency in Lahore, Pakistan. Additionally, a comparative analysis was conducted with Seratec® HemDirect (S_HD) strips to evaluate the economic feasibility of both methods. The internal validation included assessments of sensitivity, specificity, and an analysis of real-case work samples to determine the viability of the antibody as a confirmatory test for human blood. Although Ah-HB had lower sensitivity in detecting human blood at higher dilutions (1:10,000), it offered a more cost-effective solution per sample compared with S_HD, which demonstrated higher sensitivity (1:2,000,000) but at a significantly higher cost per sample. Specificity tests revealed no cross-reactivity with nonhuman blood for both Ah-HB and S_HD. This study emphasizes the importance of selecting suitable antibodies for forensic analysis by evaluating sensitivity, specificity, and cost-effectiveness. Ah-HB emerges as a valuable tool for forensic laboratories, providing reliable results at a lower cost compared with S_HD, thereby enhancing the efficiency and effectiveness of criminal investigations.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"71-76"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Reassurance Falls Short: Rethinking Vaccine Risk Communication. 当保证不足：重新思考疫苗风险沟通。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-06 DOI: 10.1177/21679436251366315

Thomas Kieber-Emmons

引用次数: 0

Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review. 免疫疗法治疗动脉粥样硬化性疾病：综合综述。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-06-01 DOI: 10.1089/mab.2025.0005

Lenize da Silva Rodrigues, Matheus Bertanha

{"title":"Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review.","authors":"Lenize da Silva Rodrigues, Matheus Bertanha","doi":"10.1089/mab.2025.0005","DOIUrl":"10.1089/mab.2025.0005","url":null,"abstract":"Immunotherapy, especially monoclonal antibodies, has shown efficacy in modulating the inflammatory response and controlling lipidic pathways, offering new approaches for treating atherosclerotic disease. This article reviews the scientific evidence on the use of therapeutic monoclonal antibodies in treating atherosclerotic disease. An integrative review was carried out using the protocol Whittemore and Knafl framework and the PRISMA 2020 guidelines for systematic reviews. We analyzed clinical trials using monoclonal antibody immunotherapy to treat atherosclerosis. This review used the relevant articles published in Scopus, Embase, PubMed, Cochrane, Web of Science, Scielo, BVS, and Cinhal databases. The period of publication studies that was selected was between 2015 and 2025. Results: 277 articles were identified. One hundred and 22 studies were in duplicate and were excluded. After the complete reading of the studies, only 20 clinical studies were included in this review, both randomized and nonrandomized. Monoclonal antibody immunotherapy presents an innovative approach to treating atherosclerosis by targeting inflammation and lipidic pathway factors. However, these treatments need to be thought out individually, and further research is required to optimize them, minimize risks, and address cost challenges. Combining immunotherapy with other therapies could promote a significant advancement in atherosclerosis management.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"44 3","pages":"53-68"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a Novel Anti-human EphA1 Monoclonal Antibody, Ea₁Mab-30, for Multiple Applications. 多用途抗人EphA1单克隆抗体Ea1Mab-30的研制

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-06-01 DOI: 10.1089/mab.2025.0006

Tomohiro Tanaka, Hiroyuki Suzuki, Honoka Taruta, Ayano Saga, Guanjie Li, Shiori Fujisawa, Mika K Kaneko, Yukinari Kato

{"title":"Development of a Novel Anti-human EphA1 Monoclonal Antibody, Ea1Mab-30, for Multiple Applications.","authors":"Tomohiro Tanaka, Hiroyuki Suzuki, Honoka Taruta, Ayano Saga, Guanjie Li, Shiori Fujisawa, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2025.0006","DOIUrl":"https://doi.org/10.1089/mab.2025.0006","url":null,"abstract":"Erythropoietin-producing hepatocellular receptor A1 (EphA1) is one of the Eph receptor family members, the largest group of receptor tyrosine kinases. EphA1 is expressed in various tissues and regulates cellular homeostasis by interacting with its membrane-bound ephrin ligands and other receptors. EphA1 critically correlates with the pathogenesis in several disorders, including Alzheimer's disease and cancers. Therefore, establishing sensitive monoclonal antibodies (mAbs) for EphA1 has been desired for basic research, diagnosis, and treatment. In this study, a novel specific and sensitive anti-human EphA1 mAb, clone Ea1Mab-30 (mouse IgG1, kappa), was established by the Cell-Based Immunization and Screening (CBIS) method. Ea1Mab-30 demonstrated reactivity with an EphA1-overexpressed Chinese hamster ovary-K1 cell line (CHO/EphA1), an endogenously EphA1-expressing bladder carcinoma cell line (5637), and a colorectal adenocarcinoma cell line (Caco-2) in flow cytometry. Crossreactivities of Ea1Mab-30 with other Eph receptors were not observed. Furthermore, the values of apparent binding affinity for CHO/EphA1 and 5637 were determined to be 8.9 × 10-9 M and 1.7 × 10-9 M, respectively. Furthermore, Ea1Mab-30 detected EphA1 protein in CHO/EphA1 and 5637 lysates using Western blot analysis. Ea1Mab-30 also clearly stained EphA1 of formalin-fixed paraffin-embedded CHO/EphA1 using immunohistochemistry. Ea1Mab-30, established by CBIS method, could help analyze the EphA1-contributed cellular functions and have potential applications in pathological diagnosis and treatment with specificity and high affinity for EphA1-expressing cells.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"44 3","pages":"41-52"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Call for Submissions: Role of Artificial Intelligence and Machine Learning in Antibody Science. 征稿：人工智能和机器学习在抗体科学中的作用。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI: 10.1089/mab.2025.0001

Andrei Moroz, Cory L Brooks

引用次数: 0

Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment. 乳腺癌治疗临床试验中的单克隆抗体。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1089/mab.2024.0018

Rahaman Shaik, Varikuppala Mounika, Shireen Begum, Agolapu Rajkumar, Bathurasi Mallikarjun, Vollala Sri Harshini, Rajini Kolure, Basavaraju Sreevani, Sneha Thakur

{"title":"Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment.","authors":"Rahaman Shaik, Varikuppala Mounika, Shireen Begum, Agolapu Rajkumar, Bathurasi Mallikarjun, Vollala Sri Harshini, Rajini Kolure, Basavaraju Sreevani, Sneha Thakur","doi":"10.1089/mab.2024.0018","DOIUrl":"10.1089/mab.2024.0018","url":null,"abstract":"One of the most potent therapeutic and diagnostic agents in contemporary medicine is the monoclonal antibody (mAb). mAbs can perform a variety of tasks in breast cancer (BC), including identifying and delivering therapeutic medications to targets, preventing cell development, and suppressing immune system inhibitors including directly attacking cancer cells. mAbs are one of the most effective therapeutic options, particularly for HER2, but they have not been well studied for their use in treating other forms of BC, particularly triple negative breast tumors. Bispecific and trispecific mAbs have created new opportunities for more targeted specific efficacy, which has a positive impact on the viability of antigen specificity. They are more versatile and effective than other forms of treatment, emerging as most popular option for treating BC. However, mAbs have a limit in treatment due to certain adverse effects, including fever, shaking, exhaustion, headache, nausea, and vomiting, as well as rashes, bleeding, and difficulty breathing. To examine the current and prospective future capacities of mAbs with regard to the detection and treatment of BC, the present review highlights advantages and disadvantages of mAb approach.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"17-39"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Dire Moment for American Biomedical Research. 美国生物医学研究的可怕时刻。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-04-01 DOI: 10.1089/mab.2025.0003

Cory L Brooks

引用次数: 0

Call for Submissions: Role of Artificial Intelligence and Machine Learning in Antibody Science. 征稿：人工智能和机器学习在抗体科学中的作用。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-02-20 DOI: 10.1089/mab.2025.0001

Andrei Moroz, Cory L Brooks

引用次数: 0

A Humanized Monoclonal Antibody Against CD300A Ameliorates Acute Ischemic Stroke in Humanized Mice. 抗CD300A人源化单克隆抗体改善人源化小鼠急性缺血性卒中

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-13 DOI: 10.1089/mab.2024.0027

Fumie Abe, Chigusa Nakahashi-Oda, Hanbin Lee, Bao Duy Tran-Duc, Kazuko Shibuya, Akira Shibuya

{"title":"A Humanized Monoclonal Antibody Against CD300A Ameliorates Acute Ischemic Stroke in Humanized Mice.","authors":"Fumie Abe, Chigusa Nakahashi-Oda, Hanbin Lee, Bao Duy Tran-Duc, Kazuko Shibuya, Akira Shibuya","doi":"10.1089/mab.2024.0027","DOIUrl":"10.1089/mab.2024.0027","url":null,"abstract":"CD300a and CD300A, among the CD300 immunoglobulin (Ig)-like receptor family members in mice and humans, respectively, are expressed on myeloid cell lineage. The interaction of CD300a and CD300A with their ligands phosphatidylserine and phosphatidylethanolamine, respectively, exposed on the plasma membrane of dead cells mediate an inhibitory signal in myeloid cells. We previously reported that a neutralizing antimouse CD300a monoclonal antibody (mAb) enhanced efferocytosis by macrophages and ameliorated acute ischemic stroke (AIS) in mice. Unlike mouse CD300a, human CD300A has a single nucleotide polymorphism (SNP, rs2272111) encoding a nonsense mutation of glutamine (CD300AQ111) instead of arginine (CD300AR111) at residue 111. In this study, we show that the SNP frequency is 32%-35% for the heterozygous allele and 4%-5% for the homozygous alleles, except Africa. In addition, we developed a humanized antihuman CD300A mAb, named TNAX103, that recognizes both CD300AR111 and CD300AQ111. We show that TNAX103 interfered with the binding of CD300AR111 and CD300AQ111 to dead cells. In addition, the injection of TNAX103 decreased neurological scores and prolonged survival in humanized mice after middle cerebral artery occlusion. These results suggest that TNAX103 may be potentially useful for the treatment of patients expressing either CD300AR111 or CD300AQ111 with AIS.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"2-7"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0